Mitocholine has discovered, patented, and is commercializing a groundbreaking nutritional composition for everyday intake that effectively addresses multiple age-related challenges and nutritional deficiencies.  A rapidly mounting body of research has shown that age related cognitive decline is caused by diminishing cell energetics: a decline in the energy level in the brain cells.  Our first product is a breakthrough formula that increases metabolic receptiveness to insulin in the brain, bringing more glucose into the brain cells, and optimizes its utilization while generating energy (ATP).  Our first product is in a proof-of-concept human clinical study involving people with mild cognitive impairment (MCI) and is expected to show strong promise to improve executive function and various markers related to cell energetics. There is a rapidly growing body of evidence that improving cell energetics could be a means of impeding the onset of dementia.  Related compositions and a pipeline of additional products will demonstrate additional, mechanistically related benefits for people of all ages.

Biotechnology

Health Care

Life Sciences

Medical Devices

Mitocholine Ltd

Mitocholine Ltd's headquarters in London, United Kingdom

Description

People

Jobs